Medidata NEXT China 2023: Digital Innovation and Artificial Intelligence Lead the Transformation of China’s Life Sciences Industry
Experts at NEXT China 2023 Conference Discuss the Digitalized and Intelligent Future of Drug Research, Development, and Commercialization
SHANGHAI, China, Sept. 7 2023- Life sciences experts, scholars, and delegates from across the globe gathered at the W Hotel on the Bund to discuss how digital innovation and artificial intelligence are transforming China’s pharmaceutical and life sciences sector at NEXT Shanghai 2023, a conference organised by Medidata, a Dassault Systèmes company.
Focusing on the theme "Gathering the Minds, Creating the Future", the first in-person NEXT Shanghai conference to be held in three years showcased 30 distinguished guest speakers who shared their digital innovations and explored the future of digital applications in the life sciences industry. Delegates learned how digital intelligence is helping to transform the patient journey for participants in clinical trials, providing enhanced data management and insights and accelerating drug research and development.
Among the keynote speeches, Edwin Ng, Senior Vice President, and General Manager, Medidata Asia Pacific firstly demonstrate the whole landscape of life science engagement of Dassault Systèmes and how it empowers the industry with end-to-end solutions; Fareed Melhem, Senior Vice President, Head of Medidata AI and Jeff Ventimiglia, Senior Vice President, Product Support and Operations, Medidata, presented the keynote by exchanging insights on the topic of Digital Intelligence Innovations for a New Era of Pharmaceutical Research. Xiaojing Zhan, Senior Vice President, Global Safety and Pharmacovigilance, Junshi Biologicals, shared the innovative application of decentralised clinical trials solutions in its global multi-sites trials under the title of "Innovation as the Wings, Based in China and Layout Globally". Prof. Jin Li, Director of the Department of Medical Oncology at Oriental Hospital of Tongji University, President of Eastern Clinical Center of Oncology Council, from the perspective of a research institution, affirmed the inevitable transformation of digital intelligence in clinical trials and the pioneering new model of local cooperation for oncology trials with Medidata; and Prof. Xia Jielai, Chairman of the Biostatistics Expert Committee of Air Force University of Medical Sciences, shared in-depth insights into the regulatory environment for the application of digitalization and the application of advanced analytics in clinical trials.
Medidata has witnessed the meteoric rise of China’s local pharmaceutical sector since 2015, due in large part to the accelerated new drug discovery and development processes. Together with about 600 customers and 40 Clinical Research Organization (CRO) partners, Medidata has supported more than 3,160 clinical trials and served more than 480,000 patients, making it a key leader in the digital transformation of China's life sciences sector.
"With the steady advancement of the digital economy in China, local pharmaceutical companies are accelerating the roll out of digital intelligence, and we have been fortunate to grow with the industry. Currently, four domestically produced PD-1 drugs have successfully been included in the national medical insurance, and the development of all these drugs has been supported by Medidata's technology. Meanwhile, Medidata integrates global resources and leading technologies to support local pharma and biotech companies to go abroad. Medidata supported the first Chinese innovative drug approved by the FDA, “said Wei (Jennifer) Li, Vice President, General Manager, Medidata Greater China. “Medidata will keep our local services 'in China, for China', to empower China's new drug R&D to go to the next level, so that more patients can benefit.”
Throughout the conference, dozens of experts also shared their insights on the practical application of digital solutions such as Decentralised Clinical Trials (DCTs), Electronic Clinical Outcome Assessment (eCOA), Randomization and Supply System (RTSM), and Risk-Based Quality Management as well as focusing on the topics of AI to improve clinical trial design and optimise site selection.
During the breakout “Digital Intelligence for Drug R&D”, delegates also explored how cutting-edge applications of digital intelligence in drug discovery can accelerate innovative drug discovery in China and improve laboratory quality management and shared the thoughts on the future of new technology application in Bio-techs and the builds of intelligent labs for the industry. The advantages of BIOVIA Discovery Studio, ONE Lab and sciences in the age of personalised medicine with the first end-to-end scientific and business platform, from research to commercialization.
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 2,100+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata
About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE® Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com
© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries.